Are herbals as safe as their advocates believe?

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 13-16

  Seeff, Leonard B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; KAVA;

ALTERNATIVE MEDICINE; BACILLUS SUBTILIS; CHOLESTATIC HEPATITIS; CHRONIC LIVER DISEASE; DISEASE SEVERITY; DRUG INDUSTRY; EDITORIAL; HEALTH CARE COST; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER INJURY; PRIORITY JOURNAL;

CHRONIC DISEASE; COMPLEMENTARY THERAPIES; HEPATITIS; HERBAL MEDICINE; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; NUTRITION SURVEYS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 56949097362     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.10.015     Document Type: Editorial

References (35)

1. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
2. Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329 (2004) 15-19
3. McDonnell P.J., and Jacobs M.R. Hospital admissions resulting from preventable adverse drug reactions. Ann Paharmacother 36 (2002) 1331-1336
4. Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., and Annest J.L. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296 (2006) 1858-1866
5. Wester K., Jonsson A.K., Spigset O., Druid H., and Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65 (2007) 573-579
6. Leone R., Sottosanti L., Luisoa Iorio M., Santuccio C., Conforti A., Sabatini V., et al. Drug-related deaths: an analysis of the Italian spontaneous reporting database. Drug Saf 31 (2008) 703-713
7. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., and Delbanco T.L. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328 (1993) 246-252
8. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280 (1998) 1569-1575
9. Radimer K., Bindewald B., Hughes J., Ervin B., Swanson C., and Picciano M.F. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey: 1999-2000. Am J Epidemiol 160 (2004) 339-349
10. Timbo B.B., Ross M.P., McCarthy P.V., and Lin C.T. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 106 (2006) 1966-1974
11. Seeff L.B., Lindsay K.L., Bacon B.R., Kresina T.F., and Hoofnagle J.H. Complementary and alternative medicine in chronic liver disease. Hepatology 34 (2001) 595-603
12. Strader D.B., Bacon B.R., Lindsay K.L., La Brecque D.R., Morgan T., Wright E.C., et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 97 (2002) 2391-2397
13. Seeff L.B., Curto T.M., Szabo G., Everson G.T., Bonkovsky H.L., Dienstag J.L., et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 47 (2008) 605-612
14. Stickel F., Patsenker E., and Schuppan D. Herbal hepatotoxicity. J Hepatol 43 (2005) 901-910
15. Furbee R.B., Barlotta K.S., Allen M.K., and Holstege C.P. Hepatotoxicity associated with herbal products. Clin Lab Med 26 (2006) 227-241
16. Seeff L.B. Herbal hepatotoxicity. Clin Liver Dis 11 (2007) 577-596
17. Modi A.A., Wright E.C., and Seeff L.B. Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review. Antivir Ther 12 (2007) 285-295
18. US Food and Drug Administration. Overview of dietary supplements. US Food and Drug Administration, Center for Food Safety and Applied Nutrition; 2003. Available from: http://vm.cfsan.fda.gov/~dms/ds-oview.html#regulate.
19. Calipai G. European legislation on herbal medicines: a look into the future. Drug Saf 31 (2008) 428-431
20. Favreau J.T., Ryu M.L., Braunstein G., Orshansky G., Park S.S., Coody G.L., et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 136 (2002) 590-595
21. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products: United States, Germany, and Switzerland, 1999-2002. MMWR Morb Mortal Wkly Rep 2002;51:1065-1067.
22. Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 57 (2002) 891-896
23. Centers for Disease Control and Prevention. Lead poisoning associated with use of Ayurvedic medication - five states, 2000-2003. MMWR Morb Mortal Wkly Rep 2004;53:582-584.
24. Saper R.B., Phillips R.S., Sehgal A., Khouri N., Davis R.B., Paquin J., et al. Lead, mercury,and arsenic in US- and Indian-manufactured Ayurvedic medicines sold over the internet. JAMA 300 (2008) 915-923
25. Joshi D., Cross T.J.S., and Wong V.S. Acute drug induced hepatitis secondary to a weight loss product purchased over the internet. Nutr J 6 (2007) 13-15
26. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008 September 17 [Epub ahead of print].
27. Wai C.T. Presentation of drug-induced liver injury in Singapore. Singapore Med 47 (2006) 116-120
28. Benichou C., and Uclaf R. Criteria of drug-induced disorders: report of an international consensus conference. J Hepatol 11 (1990) 272-276
29. Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liangpunsakul S., Watkins P.B., et al. Reliability of the Roussel Uclaf Causality Assessment method for assessing causality in drug-induced liver disease. Hepatology 48 (2008) 1175-1183
30. ® nutritional supplements contaminated with Bacillus subtilis. J Hepatol 50 (2009) 111-117
31. Liu Z.X., and Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 6 (2002) 755-774
32. ® nutritional supplements and acute hepatotoxicity. J Hepatol 47 (2007) 514-520
33. ® products. J Hepatol 47 (2007) 521-526
34. Duque J.M., Ferreiro J., Salgueiro E., and Manso G. Hepatotoxicity associated with the consumption of herbal slimming products. Med Clin I (Barc.) 128 (2007) 238-239
35. Ignarro L., Heber D., Steven Henig Y., and Bejar E. Herbalife nutritional products and liver injury revisited. J Hepatol 49 (2008) 291-293